l e t t e r s 4 4 2 VOLUME 18 | NUMBER 3 | MARCH 2012 nature medicine experiments and further confirmed by enzyme-linked immunospot (ELISPOT) (Supplementary Fig. 2 ). Subjects on a gluten-free diet (GFD) (n = 12, duration 12-156 months) showed fewer TG2-specific ASCs, whereas in control subjects the corresponding numbers were not above background. Subject data are provided in Supplementary  Table 1 and Supplementary Figure 3 . The intestinal ASCs were Ki-67 − HLA-DR low/− CD20 − CD19 low/+ ( Fig. 2c and Supplementary  Fig. 4 ), thus resembling terminally differentiated bone marrow plasma cells rather than circulating plasmablasts 4, 13 . The gut-homing marker β 7 integrin was mainly expressed on CD19 + cells ( Supplementary  Fig. 4 ). On the basis of these findings, we conclude that the duodenal plasma cell compartment in celiac disease is heavily skewed toward the production of TG2-specific IgA and that this contributes to the local plasmacytosis.
Celiac disease is an immune-mediated disorder in which mucosal autoantibodies to the enzyme transglutaminase 2 (TG2) 1 are generated in response to the exogenous antigen gluten 2 in individuals who express human leukocyte antigen HLA-DQ2 or HLA-DQ8 (ref. 3) . We assessed in a comprehensive and nonbiased manner the IgA anti-TG2 response by expression cloning of the antibody repertoire of ex vivo-isolated intestinal antibody-secreting cells (ASCs). We found that TG2-specific plasma cells are markedly expanded within the duodenal mucosa in individuals with active celiac disease. TG2-specific antibodies were of high affinity yet showed little adaptation by somatic mutations. Unlike infection-induced peripheral blood plasmablasts 4 , the TG2-specific ASCs had not recently proliferated and were not short-lived ex vivo. Altogether, these observations demonstrate that there is a germline repertoire with high affinity for TG2 that may favor massive generation of autoreactive B cells. TG2-specific antibodies did not block enzymatic activity and served as substrates for TG2-mediated crosslinking when expressed as IgD or IgM but not as IgA1 or IgG1. This could result in preferential recruitment of plasma cells from naive IgD-and IgM-expressing B cells, thus possibly explaining why the antibody response to TG2 bears signs of a primary immune response despite the disease chronicity.
Celiac disease, affecting about 1% of the populations of Europe and the United States, is a disorder caused by intolerance to the gluten proteins of wheat, barley and rye and characterized both by cellmediated immunity to gluten and by humoral responses to gluten as well as to TG2 (ref. 5) . The disease lesion in the upper small bowel is characterized by villous blunting, epithelial crypt cell hyperplasia and leukocyte infiltration including plasmacytosis in the lamina propria. CD4 + T cells recognizing deamidated gluten peptides in the context of the disease-associated HLA-DQ molecules drive the immune reaction that causes the lesion 5 . The gluten peptide deamidation is mediated by TG2 (ref. 6 ), but how autoantibodies are generated against this enzyme, which is essential for T cell epitope formation, is not known. TG2 also catalyzes a transamidation reaction by which covalent protein-protein crosslinks can be formed. It has been hypothesized that complexes of TG2 and gluten can act as a hapten-carrier, allowing gluten-reactive T cells to provide help to TG2-specific B cells 7 .
TG2-specific antibodies are a key feature of celiac disease. Although in celiac disease other autoantigens such as collagen are also targeted, it is TG2-specific IgA that is primarily used for diagnosis, with sensitivity and specificity close to 100% (ref. 8). Even in rare cases of seronegativity for TG2-specific antibodies, it seems that such antibodies are produced, as suggested by the presence of deposits in the intestine 9 . Given their increasing significance in clinical practice, it is important to establish how they are generated. Intestinal TG2-specific antibodies have been isolated by phage display 10 , but these antibodies have nonauthentic immunoglobulin Vh and Vl domain pairing. Here, by combining staining and isolation of TG2-specific plasma cells with expression cloning of antibody genes from single cells, we fully characterize the TG2-specific antibody response in the lesions of individuals with active celiac disease.
We used biotinylated TG2 and fluorescently labeled streptavidin to visualize TG2-specific ASCs by immunofluorescence in duodenal biopsy cryosections. In active celiac disease samples, but not in healthy control samples, we observed at high abundance TG2-positive cells, the majority of which expressed the plasma cell marker CD138 (Fig. 1a-g and Supplementary Fig. 1a-c) . A biotinylated control protein (BSA) did not stain any cells (Fig. 1h) . IgA dominated the response over IgM (Fig. 1f and Supplementary  Fig. 1d) , and the IgG anti-TG2 response was very limited (Supplementary Figs. 1 and 2) .
IgA and IgM plasma cells of the small intestine express surface immunoglobulins 11, 12 , thus allowing detection of antigen-specific cells with labeled TG2 multimers by flow cytometry (Fig. 2a) . Analysis of subjects with untreated celiac disease (n = 13) revealed a high abundance in the small intestine of TG2-specific ASCs (mean 10%, range 4.5-23.8%; Fig. 2b) , consistent with the tissue staining experiments and further confirmed by enzyme-linked immunospot (ELISPOT) (Supplementary Fig. 2 ). Subjects on a gluten-free diet (GFD) (n = 12, duration 12-156 months) showed fewer TG2-specific ASCs, whereas in control subjects the corresponding numbers were not above background. Subject data are provided in Supplementary  Table 1 and Supplementary Figure 3 . The intestinal ASCs were Ki-67 − HLA-DR low/− CD20 − CD19 low/+ ( Fig. 2c and Supplementary  Fig. 4 ), thus resembling terminally differentiated bone marrow plasma cells rather than circulating plasmablasts 4, 13 . The gut-homing marker β 7 integrin was mainly expressed on CD19 + cells ( Supplementary  Fig. 4 ). On the basis of these findings, we conclude that the duodenal plasma cell compartment in celiac disease is heavily skewed toward the production of TG2-specific IgA and that this contributes to the local plasmacytosis.
We then sorted single TG2 + plasma cells and from these cloned and expressed 63 recombinant human monoclonal antibodies (hmAbs) (16, 3, 38 and 6 hmAbs from four subjects). We observed reactivity to TG2 by ELISA for 49/63 hmAbs (Fig. 2d) , with the best binders showing high avidity estimated at 1 × 10 −11 M. Typically, celiac disease autoantibodies show a specific pattern of recognition of TG2 in the endomysium, the layer of connective tissue surrounding muscle fibers. We confirmed endomysial antibody (EMA) reactivity for 47/49 cloned hmAbs ( Supplementary Fig. 5) ; furthermore, 8 of the 14 low-affinity antibodies with only slight reactivity by ELISA scored positive in the EMA assay, giving a final count of 57/63 TG2-specific hmAbs (90% selection efficiency). Of 15 hmAbs cloned from the TG2 − ASCs of one of the subjects, some showed weak reactivity to TG2 in ELISA, but only one was specific Fig. 6 ). The epitopes recognized on TG2 were conformational, and none of the hmAbs were cross-reactive to gliadin, a gluten protein.
Supplementary Table 2 reports the characteristics of the hmAbs. On the basis of these observations, we conclude that the hmAbs generated were truly representative of celiac disease autoantibodies. The TG2-specific antibody repertoire was dominated by usage of few antibody variable genes. In an analysis of 60 TG2-specific antibody sequences (57 from TG2 + cells and one from TG2 − cells, plus two identical clonal sequences), the Vh5-51 gene segment dominated the Vh repertoire (44%, Fig. 3a) , consistently for all four subjects (Fig. 3b) and consistent with phage display data 10 . Also, on the basis of single-cell PCR amplification frequencies, 95% of the TG2-specific antibodies contained κ light chains (versus 55-60% normally), in particular of the VK1 family (79%, Supplementary Table 2) . Notably, the TG2-specific antibodies had only limited accumulation of somatic mutations (Fig. 3c) , but, nevertheless, they showed high avidity even when entirely encoded by germline sequences (4/60, avidity up to 3 × 10 −10 ). Thus, TG2 autoreactivity does not represent a byproduct of affinity maturation for binding to foreign antigens 14, 15 , nor is it formed by unmutated natural antibodies with broad nonspecific binding, as shown by the EMA assay and by normal frequencies of polyreactivity to DNA and nuclear antigens (Supplementary Fig. 7) . The extent of clonal relatedness, a measure of clonal expansion, was also limited, with only four pairs of clonally related hmAbs. TG2-specific antibodies appear as intestinal deposits in celiac disease in the absence of symptoms 16 , suggesting that the response is initiated months or years before diagnosis 17 . A long-term presence of TG2-specific antibodies prior to diagnosis is likely in the four adult subjects analyzed, as they reported long-lasting abdominal discomfort prior to the study. One would therefore predict persistent hypermutation and clonal expansion between the appearance of the response and the diagnosis or sampling, considering the chronic exposure to the etiologic agent (gluten) and the autoantigen (TG2).
Finding optimal models for comparison is not simple, as few human autoantibody gene sequences related to a mucosal autoimmune response have been reported. Recent studies by our group on rotavirus-specific plasma cells 11 (Fig. 3c) and by others 12 on intestinal plasma cells provide the only available examples where the target antigens of the cloned human intestinal antibodies are known. In both cases, the antibody genes were highly mutated 12 . Furthermore, some other viral diseases such as influenza and HIV, which share similarities to celiac disease in terms of repetitive or chronic exposure to the antigen, are characterized by a high degree of somatic hypermutation 4, 18 . Generation of the TG2-specific response outside of germinal centers at extrafollicular sites where only limited somatic hypermutation occurs 19 could possibly explain the observed scarce mutations. In mouse models it has been demonstrated that high affinity drives the expansion of such a plasmablast population 20 , and this could explain the near-germline Vh5-51-encoded hmAbs binding with high affinity. However, the Vh5-51-encoded hmAbs had significantly fewer mutations (P = 0.005) and, on average, a twofold lower affinity for TG2 than those encoded by other genes (Fig. 3c,d) , suggesting some contribution of somatic mutations to binding strength. The exceptionally low mutation rate in Vh5-51 may be a particular feature of this Vh gene segment 21 . The mutations preferentially targeted activationinduced cytidine deaminase hotspots (Supplementary Fig. 8 ). To address whether TG2-specific cells had undergone affinity-driven maturation, we reverted a selected panel of nine hmAbs to their germline sequence. All of the reverted TG2-specific hmAbs retained binding, eight of them with decreased yet still relatively high affinity (Supplementary Fig. 8 ). This suggests that TG2-specific B cells have Fig. 2d ). Red bars indicate means and P values were generated by Student's t-test. *P < 0.05. **P < 0.01. ***P < 0.001.
npg undergone affinity-driven maturation in the germinal center, but to a very limited extent, despite the chronic exposure to the triggering agents. Absence of TG2-specific IgA memory B cells in the peripheral blood of humans with active celiac disease, as assessed by flow cytometry (data not shown) and ELISPOT on stimulated cells (0 TG2 + out of 7.54 × 10 3 ± 3.55 × 10 3 IgA + cells; five subjects tested), may also indicate limited germinal center activity or, alternatively, drainage of TG2-specific memory B cells from blood. Class switching efficiently occurred, as the great majority of TG2-specific plasma cells expressed IgA. Finally, undetectable levels of AID transcripts ( Supplementary  Fig. 9 ) suggest that switching happened outside the mucosa rather than within it, in a fashion similar to what has been described for B cells in the colon 22 .
A scenario thus takes shape where a vigorous primary response is maintained, further germinal center activity is limited or suppressed, and there is continuous triggering of TG2-specific naive rather than memory B cells. This may result from the autoreactive nature of these cells, which seem to be recruited into germinal centers to a lesser extent 23 or rapidly exit and undergo apoptosis 24 because of peripheral immune tolerance mechanisms. Our data indicate generation of an early and massive burst of plasmablasts with relatively high affinity, and we suggest that the intrinsic yet specific autoreactivity to TG2 may allow naive B cells to exceed the affinity threshold to proliferate and give rise to such abundant progeny 25 . Further supporting this view, we propose a mechanistic model for enhanced activation of naive B cells involving crosslinking of the B cell receptor (BCR) by TG2. We engineered a recombinant hmAb to express heavy chains of different isotypes and found that TG2-specific hmAbs in IgD and to a small extent IgM, but not IgA1 or IgG1, forms are substrates for TG2 and become covalently crosslinked ( Fig. 4a and Supplementary Fig. 10 ). Crosslinking of BCRs or covalent linkage of antigen to BCR decreases the threshold for B cell activation 26 . These factors taken together would increase the likelihood for activation of naive TG2-specific B cells compared to isotype-switched IgA-or IgG-expressing memory B cells. As this model builds on the requirement that TG2 be enzymatically active while bound to the BCR, we tested whether the hmAbs affected TG2 enzymatic activity (Fig. 4b,c and Supplementary Fig. 11 ). Only one of 47 assayed hmAbs had a substantial inhibitory effect on TG2 enzymatic activity, and interference with conformational activation of TG2 seemed to be the mechanism of inhibition. In vivo, antibodies will bind TG2 in extracellular regions that have high Ca 2+ concentrations, and in this setting none of the tested hmAbs would be inhibitory. Thus, the antibodies do not seem to exert a pathogenic role by inhibiting TG2 enzymatic activity.
Another key question is whether TG2-specific antibody formation results from a T cell-dependent or T cell-independent B cell response, the latter suggested by scarce somatic hypermutation 27 . In mice, many intestinal IgA plasma cells are derived from peritoneal B1 cells in a T cell-independent fashion 28, 29 . However, the clinical observation of strict gluten-and HLA-dependent appearance of TG2-specific antibodies 2,3 strongly suggests that T cells have a role. Because the selection of high-affinity B cells during affinity maturation is primarily dependent on the presentation of peptides to T cells 30 , T cell help is further supported by the observed loss of affinity when mutations were removed (Supplementary Fig. 8 ). In addition, we show here that B cells engineered to express a TG2-specific BCR are able to process and present TG2-gliadin complexes resulting in activation of gluten-specific T cells derived from subjects with celiac disease (Supplementary Fig. 12 ). On the basis of these observations and findings, we favor a T cell-dependent model in the generation of the antibodies 7 .
Evidence suggests that TG2-specific ASCs in the intestinal mucosa are not renewed at a high rate. The cells are Ki-67 − , and the TG2-specific compartment is not replenished by circulating ASCs (0 out of 1.93 × 10 3 ± 2.25 × 10 3 IgA + cells, as assayed by ELISPOT; three subjects tested). The long lifespan of TG2-specific ASCs seems to contribute more to the preservation of this large cell population. Mucosal ASCs can be long-lived 31, 32 , especially in the niche provided by the inflamed mucosa of people with celiac disease 33 . Consistent with this, cultured duodenal biopsies secreted TG2-specific IgA antibodies for several weeks (Supplementary Fig. 13) .
The presence of TG2-specific IgM plasma cells ( Fig. 1 and  Supplementary Fig. 1 ) suggests one possible pathogenic role for TG2-specific antibodies. Unlike IgA, IgM can activate complement via the classical pathway and may thus contribute to celiac disease inflammation 34 , especially in IgA-deficient individuals 35 . TG2-specific B cells may also be essential in the pathogenesis of celiac disease by acting as APCs for the antigluten T cell response. Inhibiting this amplification loop could represent a new strategy for treatment of celiac disease. Figure 11 . (c) Effect of the mouse TG2-specific mAb CUB7402 (positive control), mouse IgG1 isotype control, control hmAbs not reactive to TG2 (n = 10) and anti-TG2 hmAbs (n = 47) on the enzymatic activity of TG2. Residual activity on the y axis is defined as the relative activity of each hmAb as compared with a non TG2-reactive isotype control hmAb, the activity of which is set to 1.
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In conclusion, this study provides, to our knowledge, the first comprehensive dissection of a mucosal antibody response directly from the effector compartment. It reveals several previously unrecognized aspects of the TG2-specific autoantibody response in celiac disease, primarily the abundance and mutation profile of TG2-specific plasma cells, and the limited inhibitory activity of the antibodies. In a broader context, this study presents new methodologies to study autoimmune responses, especially those where plasma cell activity in the affected organ is thought to be relevant, such as rheumatoid arthritis and multiple sclerosis.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
